Patents by Inventor Alan D. Robertson
Alan D. Robertson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150158813Abstract: The preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I: is described. Methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer, are also described.Type: ApplicationFiled: April 5, 2013Publication date: June 11, 2015Inventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan D. Robertson, Craig Ivan Turner
-
Patent number: 8557783Abstract: Methods of using phosphotetrahydropyran compounds for treatment of fibrotic and scarring disorders, e.g. pulmonary fibrosis, fibrosis associated with surgical procedures, wound healing disorders, scar formation, sclerotic disorders, ocular fibrotic disorders, ocular healing disorders, ocular fibrosis after surgery, glaucoma, tendon scarring disorders, joint scarring disorders, kidney interstitial fibrosis and glomerular fibrosis and tubular fibrosis of the kidney.Type: GrantFiled: April 28, 2010Date of Patent: October 15, 2013Assignee: Pharmaxis Pty LimitedInventors: Alan D. Robertson, Diego Silva, Ian Alexander McDonald
-
Publication number: 20120045455Abstract: Methods of using phosphotetrahydropyran compounds for treatment of fibrotic and scarring disorders, e.g. pulmonary fibrosis, fibrosis associated with surgical procedures, wound healing disorders, scar formation, sclerotic disorders, ocular fibrotic disorders, ocular healing disorders, ocular fibrosis after surgery, glaucoma, tendon scarring disorders, joint scarring disorders, kidney interstitial fibrosis and glomerular fibrosis and tubular fibrosis of the kidney.Type: ApplicationFiled: April 28, 2010Publication date: February 23, 2012Applicant: Pharmaxis Pty LimitedInventors: Alan D. Robertson, Diego Silva, Ian Alexander McDonald
-
Patent number: 7872011Abstract: The present invention relates to selective inhibitors of phosphoinositide (PI) 3-kinase ?, use of the selective inhibitors in anti-thrombotic therapy, and a method for screening compounds useful for the new anti-thrombotic therapy by detecting selective inhibitory activity of PI 3-kinase ? of the compound. The invention also relates to novel compounds that are inhibitors of PI 3-kinase.Type: GrantFiled: December 27, 2007Date of Patent: January 18, 2011Assignee: AstraZeneca ABInventors: Shaun P. Jackson, Alan D. Robertson, Vijaya Kenche, Philip Thompson, Hishani Prabaharan, Karen Anderson, Belinda Abbott, Isaac Goncalves, Warwick Nesbitt, Simone Shoenwaelder, Dilek Saylik
-
Patent number: 7598377Abstract: The present invention relates to selective inhibitors of phosphoinositide (PI) 3-kinase ?, use of the selective inhibitors in anti-thrombotic therapy, and a method for screening compounds useful for the new anti-thrombotic therapy by detecting selective inhibitory activity of PI 3-kinase ? of the compound. The invention also relates to novel compounds that are inhibitors of PI 3-kinase.Type: GrantFiled: August 18, 2003Date of Patent: October 6, 2009Assignee: AstraZeneca ABInventors: Shaun P. Jackson, Alan D. Robertson, Vijaya Kenche, Philip Thompson, Hishani Prabaharan, Karen Anderson, Belinda Abbott, Isaac Goncalves, Warwick Nesbitt, Simone Shoenwaelder, Dilek Saylik
-
Patent number: 7572791Abstract: Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation.Type: GrantFiled: January 24, 2008Date of Patent: August 11, 2009Assignee: AstraZeneca ABInventors: Alan D. Robertson, Shaun Jackson, Vijaya Kenche, Cindy Yaip, Hishani Parbaharan, Phil Thompson
-
Publication number: 20080319021Abstract: The present invention relates to selective inhibitors of phosphoinositide (PI) 3-kinase ?, use of the selective inhibitors in anti-thrombotic therapy, and a method for screening compounds useful for the new anti-thrombotic therapy by detecting selective inhibitory activity of PI 3-kinase ? of the compound. The invention also relates to novel compounds that are inhibitors of PI 3-kinase.Type: ApplicationFiled: December 27, 2007Publication date: December 25, 2008Inventors: Shaun P. Jackson, Alan D. Robertson, Vijaya Kenche, Philip Thompson, Hishani Prabaharan, Karen Anderson, Belinda Abbott, Isaac Goncalves, Warwick Nesbitt, Simone Shoenwaelder, Dilek Saylik
-
Publication number: 20080312233Abstract: Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation.Type: ApplicationFiled: May 6, 2008Publication date: December 18, 2008Inventors: Alan D. Robertson, Shaun Jackson, Vijaya Kenche, Cindy Yaip, Hishani Parbaharan, Phil Thompson
-
Publication number: 20080206312Abstract: Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation.Type: ApplicationFiled: January 24, 2008Publication date: August 28, 2008Inventors: Alan D. Robertson, Shaun Jackson, Vijaya Kenche, Cindy Yaip, Hishani Parbaharan, Phil Thompson
-
Patent number: 7405211Abstract: Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation.Type: GrantFiled: October 12, 2004Date of Patent: July 29, 2008Assignee: AstraZeneca ABInventors: Alan D. Robertson, Shaun Jackson, Vijaya Kenche, Cindy Yaip, Hishani Parbaharan, Phil Thompson
-
Patent number: 6977255Abstract: Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation.Type: GrantFiled: January 24, 2001Date of Patent: December 20, 2005Assignee: Kinacia Pty. Ltd.Inventors: Alan D. Robertson, Shaun Jackson, Vijaya Kenche, Cindy Yap, Hishani Parbaharan, Phil Thompson
-
Patent number: 5863935Type: GrantFiled: June 6, 1995Date of Patent: January 26, 1999Assignee: Zeneca LimitedInventors: Alan D. Robertson, Alan P. Hill, Robert C. Glen, Graeme R. Martin
-
Patent number: 5466699Type: GrantFiled: December 5, 1994Date of Patent: November 14, 1995Assignee: Burroughs Wellcome Co.Inventors: Alan D. Robertson, Alan P. Hill, Robert C. Glen, Graeme R. Martin
-
Patent number: 5399574Type: GrantFiled: March 3, 1992Date of Patent: March 21, 1995Assignee: Burroughs Wellcome Co.Inventors: Alan D. Robertson, Alan P. Hill, Robert C. Glen, Graeme R. Martin
-
Patent number: 5225431Abstract: The present invention is concerned with compounds of formula (I) ##STR1## wherein R, R.sup.1 and R.sup.2 are independently selected from hydrogen and C.sub.1-4 alkyl;R.sup.3 and R.sup.4 are independently selected from hydrogen, C.sub.1-6 alkyl (including cycloalkyl) and aryl (wherein the alkyl or aryl group, which latter includes benzyl, is optionally substituted by one or more atoms or groups independently selected from halogen, C.sub.1-4 alkyl and aryl), provided R.sup.3 benzyl or substituted benzyl when R.sup.4 =H;m is an integer of from 0 to 2;n is an integer of from 0 to 3;(W) is a group of formula (i), (ii), (iii), or (iv) ##STR2## wherein Y is selected from oxygen, methylene and >N--R.sup.5, where R.sup.5 is hydrogen, C.sub.1-4 alkyl, or benzyl, Z and Z' are independently selected from >C.dbd.O, >C.dbd.Type: GrantFiled: February 26, 1991Date of Patent: July 6, 1993Assignee: Burroughs Wellcome Co.Inventors: Alan D. Robertson, Graeme R. Martin, Janet S. Buckingham
-
Patent number: 5147885Abstract: N-amino hexahydrocyclopenta imidazole-2(1H)-one derivatives useful for treating or preventing thrombo-embolic disorders and ocular diseases characterized by increased ocular pressure.Type: GrantFiled: May 23, 1991Date of Patent: September 15, 1992Assignee: Burroughs Wellcome Co.Inventors: Heather Giles, Alan D. Robertson, Michael G. Kelly, Leff, Paul
-
Patent number: 4291736Abstract: A magnetic hammer having a handle and a hammer body coupled to the handle includes a cylindrical magnetic insert having first and second ends with the magnetic poles of the insert being aligned with the central axis of the insert. A cylindrical retainer having first and second ends includes a cylindrical chamber which is sized to receive and retain the magnetic insert. The axis of the magnetic insert is aligned with the axis of the cylindrical retainer and the first end of the magnetic insert and the first end of the cylindrical retainer form the hammering face of the hammer. The second end of the cylindrical retainer is coupled to the hammer body.Type: GrantFiled: July 19, 1979Date of Patent: September 29, 1981Assignees: Alan D. Robertson, Blythe J. RobertsonInventors: Alan D. Robertson, Blythe J. Robertson, Gerald Olson